Skip to content

Research on the Accurate Diagnosis of Hepatocellular Carcinoma Based on Multi-modal Ultrasound Radiomics and Molecular Pathological Markers

Research on the Accurate Diagnosis of Hepatocellular Carcinoma Based on Multi-modal Ultrasound Radiomics and Molecular Pathological Markers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126016
Enrollment
Unknown
Registered
2026-06-02
Start date
2024-01-03
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

regenerative nodule (RN):None
dysplastic nodule (DN):None
hepatocellular carcinoma (HCC):None

Sponsors

The First Affiliated Hospital,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-80 years; 2. Patients with liver cirrhosis or chronic hepatitis B infection caused by various reasons; 3. Intrahepatic focal lesions with a diameter of 5 mm <= lesion <= 2 cm; 4. Hepatocellular carcinoma must be confirmed by surgical or biopsy histopathology; diagnosis of benign nodules can be based on histopathological diagnosis or Gd-EOB-DTPA-enhanced MRI diagnosis with no changes upon follow-up after six months; 5. Intrahepatic focal lesions should undergo conventional ultrasound, contrast-enhanced ultrasound, elastography examination, and Gd-EOB-DTPA-enhanced MRI or contrast-enhanced CT examination.

Exclusion criteria

Exclusion criteria: 1.(case group and control group) Liver lesions cannot be clearly shown on 2D ultrasound, such as surrounding gas and rib occlusion; 2.Two or more liver lesions appeared in the same CEUS window (case and control group); 3.Non-cirrhotic nodules such as hepatic hemangioma, hepatic cyst, and focal hepatic nodular hyperplasia were diagnosed; 4.(Case group and control group) The lesion underwent local or systemic antitumor therapy; 5.(case group and control group) with other malignancies;

Design outcomes

Primary

MeasureTime frame
Accuracy;Sensitivity;Specificity;

Countries

China

Contacts

Public ContactXu Ming

The First Affiliated Hospital,Sun Yat-sen University

xuming8@mail.sysu.edu.cn+86 20 8776 5183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026